|
Jul 26
|
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
|
|
Jun 18
|
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
|
|
Apr 7
|
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
|
|
Mar 29
|
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
|
|
Jan 10
|
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
|
|
Jan 2
|
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
|
|
Dec 2
|
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
|